Athira Pharma logo

Athira Pharma

athira.com

Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.

Facts

HQ
Seattle
Sectors
Biopharmaceuticals, Biotech, Pharmaceuticals
Employees
30
Stage
Series B

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about Athira Pharma

See all 41

EIT Pharma, led by ex-Athira CEO Leen Kawas, raises $35M Series A to advance lonafarnib for chronic hepatitis D

Kirkland-based EIT Pharma, led by former Athira CEO Leen Kawas, raised $35 million in an oversubscribed Series A led by Propel Bio Partners to support FDA review, manufacturing and commercial preparations for lonafarnib as an oral treatment candidate for chronic hepatitis D. The FDA accepted EIT Pharma's New Drug Application for lonafarnib on Aug. 11; the drug was acquired from Eiger BioPharmaceuticals' 2024 bankruptcy sale.

People

  • Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer

Online

Questions about Athira Pharma

What is Athira Pharma?

athira.com

Who are the people behind Athira Pharma?

Seattle Flow lists Rachel Lenington (Executive, Chief Operating Officer and Chief Development Officer) at Athira Pharma.

Who invested in Athira Pharma, and how much has it raised?

Members of Seattle Flow see Athira Pharma's funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is Athira Pharma based?

Athira Pharma is headquartered in Seattle.

How many people work at Athira Pharma?

Athira Pharma has 30 employees.